5 recruiting, 4 completed, 2 terminated, 1 withdrawn. 10 Phase 2, 1 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 4, Recruiting 3, Terminated 2, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Persistent Corneal Epithelial Defect: new trials by email Literature Review of Persistent Corneal Epithelial Defect trials Research Report on Persistent Corneal Epithelial Defect
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED Cenegermin, Vehicle - Persistent Corneal Epithelial Defect | Phase 3 | Recruiting | Dompé Farmaceutici S.p.A | 150 | 2026-06-02 | 2026-10-07 |
| A Study to Evaluate the Efficacy and Safety of TP-06 for PCED TP-06, Vehicle of TP-06 - Persistent Corneal Epithelial Defect | Phase 2 | Recruiting | Tarsus Pharmaceuticals, Inc. | 32 | 2026-04-20 | 2026-10-21 |
| Comparison of Topical Insulin and Amniotic Membrane Transplant for Persistent Corneal Epithelial Defects Topical insulin eye drops, Amniotic Membrane Graft - Persistent Corneal Epithelial Defect | Phase 4 | Recruiting | Al-Shifa Trust Eye Hospital | 214 | 2026-03-27 | 2026-05-01 |
| Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control - Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders | Phase 2 | Recruiting | University of Illinois Chicago | 24 | 2025-08-01 | 2026-10-28 |
| A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED lufepirsen high dose, Vehicle, lufepirsen low dose - Persistent Corneal Epithelial Defect | Phase 2 | Recruiting | Glaukos Corporation | 84 | 2023-08-17 | 2025-07-24 |
| Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED KPI-012, KPI-012 Vehicle - Persistent Corneal Epithelial Defect | Phase 2 | Terminated | Combangio, Inc | 103 | 2023-02-07 | 2025-10-22 |
| A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S) - Persistent Corneal Epithelial Defect | Phase 2 | Completed | Kiora Pharmaceuticals, Inc. | 10 | 2022-07-01 | 2024-04-03 |
| ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects ST266, 0.67% Sodium Chloride Ophthalmic Solution, Open-label ST266 - Persistent Corneal Epithelial Defect | Phase 2 | Terminated | Noveome Biotherapeutics, formerly Stemnion | 8 | 2022-04-27 | 2022-10-25 |
| Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Trophic Ulcers LV-Visio-AMTRIX - Corneal Ulcer, Persistent Corneal Epithelial Defect | Phase 2 | Withdrawn | TBF Genie Tissulaire | 2022-04-01 | 2022-08-05 | |
| ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects ST266 - Persistent Corneal Epithelial Defect | Phase 2 | Completed | Noveome Biotherapeutics, formerly Stemnion | 13 | 2019-06-10 | 2021-08-18 |
| Autologous Platelet Lysate in Corneal Epithelial Defects Platelet Lysate - Persistent Corneal Epithelial Defect | Phase 1 / Phase 2 | Completed | Hanan Jafar | 10 | 2017-02-16 | 2021-03-03 |
| Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect DE-105 ophthalmic solution, Placebo ophthalmic solution - Persistent Corneal Epithelial Defect | Phase 2 | Completed | Santen Pharmaceutical Co., Ltd. | 45 | 2009-09-01 | 2012-11-22 |
Conjunctivitis, Allergic (1) · Corneal Ulcer (1) · Limbal Stem Cell Deficiency (1)
Eye Diseases (3) · Corneal Diseases (2) · Conjunctival Diseases (1) · Conjunctivitis (1) · Eye Infections (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Infections (1) · Keratitis (1)
cenegermin (1)
Noveome Biotherapeutics, formerly Stemnion (2) · Al-Shifa Trust Eye Hospital (1) · Combangio, Inc (1) · Dompé Farmaceutici S.p.A (1) · Glaukos Corporation (1) · Hanan Jafar (1) · Kiora Pharmaceuticals, Inc. (1) · Santen Pharmaceutical Co., Ltd. (1) · TBF Genie Tissulaire (1) · Tarsus Pharmaceuticals, Inc. (1) · University of Illinois Chicago (1)
United States (7) · Mexico (3) · Argentina (2) · Germany (2) · Italy (2) · Japan (2) · Spain (2) · Czechia (1) · Dominican Republic (1) · El Salvador (1) · France (1) · Hungary (1) · Jordan (1) · Netherlands (1) · Pakistan (1)
Abdallah Awidi, MD (1) · Ali R Djalilian, MD (1) · Enrique Graue, M.D. (1) · Kristie Veasey (1) · Luis G. Vargas, MD (1) · Shama Khan, MBBS,FCPS (1)
2025 (1), 3UH3EY031809-04S1 (1)